The Initiative for Medicines, Access, and Knowledge (I-MAK), a public interest team of attorneys and scientists who seek to ensure that patents do not obstruct patient access to affordable medicines, has issued a new report that details the number of patents drug makers have attempted to secure for the highest-grossing drugs in the United States.
The Initiative for Medicines, Access, and Knowledge (I-MAK), a public interest team of attorneys and scientists who seek to ensure that patents do not obstruct patient access to affordable medicines, has issued a new report that details the number of patents drug makers have attempted to secure for the highest-grossing drugs in the United States.
Drawing on data from drug makers’ own reports, patent databases, and IQVIA data, I-MAK found that the 12 top-selling drugs in the United States during 2017 included the high-cost biologics Humira (adalimumab), Rituxan (rituximab), Enbrel (etanercept), Herceptin (trastuzumab), Remicade (infliximab), and Avastin (bevacizumab), all of which are targeted by biosimilar developers. These products cost the US health system a total of $96 billion in 2017.
On average, the sponsors of these drugs attempted to secure 125 patents per product (range, 48-247), with the United States granting an average of 71 patents per drug (range, 27-132). According to I-MAK, these patents “are filed with a strategic intent to extend the commercial monopolies far beyond the intended [20] years of protection,” and have resulted in an average of an additional 38 years of market exclusivity per drug. This lack of competition, says the report, has allowed companies to raise their prices by an average of 68% per product since 2012.
I-MAK calls AbbVie “the worst patent offender,” having both attempted 247 patents for its Humira and raised prices by 144% since 2012. Amgen was not far behind, having raised prices on its Enbrel by 155% in the same time period, though it attempted far fewer patents (57). Roche raised its prices on Avastin by 16%, and sought to gain 219 patents for its product.
The only product for which a price decrease (—58%) was observed since 2012 was Roche and Genentech’s Herceptin, though I-MAK notes that patents pending for the drug could extend its market exclusivity until 2033.
In order to allow for price competition for these high-grossing drugs, concludes the report, the United States will need “significant policy reform.”
In an interview with The Center for Biosimilars® earlier in 2018, Tahir Amin, DipLP, the cofounder and director of intellectual property for I-MAK, said that one key way to reform the US system is to improve upon the standard of what can be patented.
“I feel the law has not kept up with the advances with how [research and development, R&D] is done, and how scientific knowledge has been accumulated over the last 50 years,” said Amin. He explained that, “In order to get your patent, you’re judged by whether it’s novel, based on what’s known in the field, or if it is obvious to someone in the field. The obviousness standard is not applied in the correct way. It’s almost as if techniques from 50 years ago are still not obvious to people, and I think the law hasn’t kept up.”
Among I-MAK’s goals, Amin said, is “…bringing that standard up to where science is today, and we’ll find that a lot of things are obvious. Patents would not be granted so readily, and only the really high-end inventions would be [patentable]. That’s where a lot of the focus needs to be on.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.